Vivani Medical Bets on Tiny Semaglutide Implant for Weight Loss

Vivani Medical is developing a miniature implant loaded with semaglutide — the active ingredient powering Novo Nordisk's blockbuster obesity drug Wegovy and its diabetes counterpart Ozempic — in a bid to help patients maintain weight loss over time without the burden of recurring injections.

The move represents one of the most ambitious efforts yet to solve a persistent problem in GLP-1 therapy: patient adherence. Many people who begin weekly injection regimens eventually stop, often leading to rapid weight regain. A long-acting implant could theoretically remove that friction by delivering a steady dose of the drug from beneath the skin over an extended period.

Read more Apple Sues OpenAI Over Alleged Trade Secret Theft by Ex-Staff →

Semaglutide has reshaped the obesity treatment landscape since its approval, generating tens of billions of dollars in annual revenue for Novo Nordisk and sparking fierce competition across the pharmaceutical sector. Vivani's implant approach, if successful, would represent a meaningful clinical and commercial differentiator in a market where delivery format is increasingly becoming a competitive battleground alongside the drugs themselves.

While the implant is still in development and has not yet reached late-stage clinical trials, it signals a broader industry trend toward next-generation delivery mechanisms for GLP-1 receptor agonists. Rivals and startups alike are racing to find formulations — oral pills, patches, and now implants — that can extend the reach of these powerful metabolic drugs to patients who struggle with self-administered injections.

Continue reading at US Top News and Analysis.